These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 12369897)
1. Permeability characteristics of endocrine-disrupting chemicals using an in vitro cell culture model, Caco-2 cells. Yoshikawa Y; Hayashi A; Inai M; Matsushita A; Shibata N; Takada K Curr Drug Metab; 2002 Oct; 3(5):551-7. PubMed ID: 12369897 [TBL] [Abstract][Full Text] [Related]
2. Atorvastatin transport in the Caco-2 cell model: contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter. Wu X; Whitfield LR; Stewart BH Pharm Res; 2000 Feb; 17(2):209-15. PubMed ID: 10751037 [TBL] [Abstract][Full Text] [Related]
3. Transport characteristics of fexofenadine in the Caco-2 cell model. Petri N; Tannergren C; Rungstad D; Lennernäs H Pharm Res; 2004 Aug; 21(8):1398-404. PubMed ID: 15359574 [TBL] [Abstract][Full Text] [Related]
4. Age-dependent expression of P-glycoprotein gp170 in Caco-2 cell monolayers. Hosoya KI; Kim KJ; Lee VH Pharm Res; 1996 Jun; 13(6):885-90. PubMed ID: 8792427 [TBL] [Abstract][Full Text] [Related]
5. Effects of endocrine disrupting chemicals on the microtubule network in Chinese hamster V79 cells in culture and in Sertoli cells in rats. Nakagomi M; Suzuki E; Usumi K; Saitoh Y; Yoshimura S; Nagao T; Ono H Teratog Carcinog Mutagen; 2001; 21(6):453-62. PubMed ID: 11746258 [TBL] [Abstract][Full Text] [Related]
6. The absorptive flux of the anti-epileptic drug substance vigabatrin is carrier-mediated across Caco-2 cell monolayers. Nøhr MK; Hansen SH; Brodin B; Holm R; Nielsen CU Eur J Pharm Sci; 2014 Jan; 51():1-10. PubMed ID: 24008184 [TBL] [Abstract][Full Text] [Related]
7. P-glycoprotein-mediated transport of berberine across Caco-2 cell monolayers. Maeng HJ; Yoo HJ; Kim IW; Song IS; Chung SJ; Shim CK J Pharm Sci; 2002 Dec; 91(12):2614-21. PubMed ID: 12434406 [TBL] [Abstract][Full Text] [Related]
8. Copper treatment alters the barrier functions of human intestinal Caco-2 cells: involving tight junctions and P-glycoprotein. Liu Z; Chen B Hum Exp Toxicol; 2004 Aug; 23(8):369-77. PubMed ID: 15346718 [TBL] [Abstract][Full Text] [Related]
9. Validation and application of Caco-2 assays for the in vitro evaluation of development candidate drugs as substrates or inhibitors of P-glycoprotein to support regulatory submissions. Elsby R; Surry DD; Smith VN; Gray AJ Xenobiotica; 2008 Jul; 38(7-8):1140-64. PubMed ID: 18668443 [TBL] [Abstract][Full Text] [Related]
10. Characterization of P-glycoprotein mediated transport of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor, across MDR1-MDCK and Caco-2 cell monolayers. Zhang Y; Benet LZ Pharm Res; 1998 Oct; 15(10):1520-4. PubMed ID: 9794492 [TBL] [Abstract][Full Text] [Related]
11. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors. Profit L; Eagling VA; Back DJ AIDS; 1999 Sep; 13(13):1623-7. PubMed ID: 10509562 [TBL] [Abstract][Full Text] [Related]
12. Caco-2 versus Caco-2/HT29-MTX co-cultured cell lines: permeabilities via diffusion, inside- and outside-directed carrier-mediated transport. Hilgendorf C; Spahn-Langguth H; Regårdh CG; Lipka E; Amidon GL; Langguth P J Pharm Sci; 2000 Jan; 89(1):63-75. PubMed ID: 10664539 [TBL] [Abstract][Full Text] [Related]
14. Endocrine disrupting chemicals, 4-nonylphenol, bisphenol A and butyl benzyl phthalate, impair metabolism of estradiol in male and female rats as assessed by levels of 15α-hydroxyestrogens and catechol estrogens in urine. Nakagomi M; Suzuki E; Saito Y; Nagao T J Appl Toxicol; 2018 May; 38(5):688-695. PubMed ID: 29250801 [TBL] [Abstract][Full Text] [Related]
15. P-Glycoprotein (P-gp) mediated efflux in Caco-2 cell monolayers: the influence of culturing conditions and drug exposure on P-gp expression levels. Anderle P; Niederer E; Rubas W; Hilgendorf C; Spahn-Langguth H; Wunderli-Allenspach H; Merkle HP; Langguth P J Pharm Sci; 1998 Jun; 87(6):757-62. PubMed ID: 9607955 [TBL] [Abstract][Full Text] [Related]
16. Role of P-glycoprotein-mediated secretion in absorptive drug permeability: An approach using passive membrane permeability and affinity to P-glycoprotein. Döppenschmitt S; Spahn-Langguth H; Regårdh CG; Langguth P J Pharm Sci; 1999 Oct; 88(10):1067-72. PubMed ID: 10514357 [TBL] [Abstract][Full Text] [Related]
17. Permeability modulation of human intestinal Caco-2 cell monolayers by interferons. Kawaguchi H; Akazawa Y; Watanabe Y; Takakura Y Eur J Pharm Biopharm; 2005 Jan; 59(1):45-50. PubMed ID: 15567300 [TBL] [Abstract][Full Text] [Related]
18. Synthesis and assessment of first-generation polyamidoamine dendrimer prodrugs to enhance the cellular permeability of P-gp substrates. Najlah M; Freeman S; Attwood D; D'Emanuele A Bioconjug Chem; 2007; 18(3):937-46. PubMed ID: 17355118 [TBL] [Abstract][Full Text] [Related]
19. Sodium glycocholate transport across Caco-2 cell monolayers, and the enhancement of mannitol transport relative to transepithelial electrical resistance. Lindhardt K; Bechgaard E Int J Pharm; 2003 Feb; 252(1-2):181-6. PubMed ID: 12550793 [TBL] [Abstract][Full Text] [Related]
20. Stereoselective and concentration-dependent polarized epithelial permeability of a series of phosphoramidate triester prodrugs of d4T: an in vitro study in Caco-2 and Madin-Darby canine kidney cell monolayers. Siccardi D; Kandalaft LE; Gumbleton M; McGuigan C J Pharmacol Exp Ther; 2003 Dec; 307(3):1112-9. PubMed ID: 14557377 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]